Medtronic PLC (MDT) Enterprise Value to EBITDA (EV/EBITDA): 14.73

Since April 30th, 2009, Medtronic PLC's enterprise value to ebitda (ev/ebitda) has increased from 11.04 to 14.73 at May 26th, 2023.

From 2009 to 2023 Medtronic PLC's highest enterprise value to ebitda (ev/ebitda) was 26.99
Medtronic PLC's lowest enterprise value to ebitda (ev/ebitda) during that period was 6.38
Medtronic PLC's average enterprise value to ebitda (ev/ebitda) from 2009 to 2023 Medtronic PLC's was 14.60

Medtronic PLC's enterprise value to ebitda (ev/ebitda) as of May 26th, 2023 of 14.73 was lower than its peers in the Medical Appliances & Equipment industry group of April 30th, 2023 of 32.63. From April 30th, 2009 to May 26th, 2023, Medtronic PLC's average enterprise value to ebitda (ev/ebitda) was 14.60 compared to an industry average of 30.73.

About Medtronic PLC

Medtronic Plc is engaged in the medical technology-alleviating pain, restoring health, and extending life for millions of people around the world. Its customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. The company operates through four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group consist of three divisions : Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascular. The Minimally Invasive Technologies Group consists of two divisions: Surgical Solutions and Patient Monitoring and Recovery. The Restorative Therapies Group consists of four divisions: Spine, Neuromodulation, Surgical Technologies and Neurovascular. The Diabetes Group consists of three divisions: Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The company was founded on January 26, 2015 and is headquartered in Dublin, Ireland.